Lilly launches Foundayo; builds compute
Eli Lilly launched Foundayo, an FDA‑approved once‑daily oral GLP‑1 obesity pill that directly competes with Novo Nordisk’s oral Wegovy and is already being offered through telehealth channels. At the same time, recent video coverage flagged Lilly assembling massive compute — a 9,000‑petaflop figure mentioned in media — showing big pharma is treating AI infrastructure as a strategic asset (biopharmadive.com) (youtube.com).
A weight-loss pill used to mean alarms, empty stomachs, and a glass of water timed like a chemistry experiment. Eli Lilly’s new pill Foundayo entered the United States on April 9 with the opposite pitch: swallow it once a day whenever you want. (biopharmadive.com) Foundayo is Lilly’s brand name for orforglipron, and the Food and Drug Administration approved it on April 1 for adults with obesity or adults with overweight plus a related medical problem. Lilly says it is now available through LillyDirect, telehealth providers, and retail pharmacies nationwide. (fda.gov) (medical.lilly.com) (prnewswire.com) These drugs copy a gut hormone called glucagon-like peptide-1, which is the body’s own “I’m full” signal after eating. The injectable versions turned obesity treatment into one of the biggest markets in medicine, and now both big players want the same effect in a pill. (foundayo.lilly.com) (biopharmadive.com) Lilly is late to the oral race, not early. Novo Nordisk won approval for its oral Wegovy pill on December 22, 2025 and launched it in early January 2026, giving it roughly a three-month head start. (prnewswire.com) (biopharmadive.com) The fight is not just pill versus pill. Novo’s oral Wegovy has stricter instructions: take it first thing in the morning on an empty stomach and wait 30 minutes before food, drink, or other medicines, while Lilly says Foundayo can be taken any time of day without food or water restrictions. (biopharmadive.com) (medical.lilly.com) Price is being used like a weapon too. BioPharma Dive reported that Foundayo starts at $149 a month for self-pay patients at the lowest dose, matching the starter price Novo set for oral Wegovy, while Lilly says some commercially covered patients may pay as little as $25 a month with a savings card. (biopharmadive.com) (prnewswire.com) Distribution is being treated like part of the drug. LifeMD and Weight Watchers said on April 10 that they are already offering Foundayo, and Amazon Pharmacy said it can deliver the pill the same day in nearly 3,000 cities and towns. (markets.businessinsider.com 1) (markets.businessinsider.com 2) (finance.yahoo.com) At the same time Lilly is building the plumbing behind the next wave of drugs. In February it switched on LillyPod in Indianapolis, a supercomputer built with 1,016 NVIDIA Blackwell Ultra graphics processors that NVIDIA says delivers more than 9,000 petaflops of artificial-intelligence performance. (blogs.nvidia.com) A petaflop is one quadrillion calculations per second, so 9,000 petaflops is the kind of number usually associated with national labs, not a drug company campus. NVIDIA says Lilly assembled the system in four months and plans to use it to train models for proteins, small molecules, and genomics. (blogs.nvidia.com) That puts the two halves of this story together. Lilly is selling a pill designed to remove friction for patients, while spending like a cloud company on computing designed to remove friction from drug discovery inside the company. (biopharmadive.com) (blogs.nvidia.com) For years big pharma bought molecules and rented compute. In April 2026, Lilly is doing both in-house: launching Foundayo into telehealth and pharmacy channels now, and stockpiling machine power that could shape the next obesity drug after this one. (prnewswire.com) (blogs.nvidia.com)
